Theranostic nanoagents enhance photothermal therapy and MRI imaging in glioma treatment, indicating improved efficacy.
Motivation: Advanced theranostic nanoagents for imaging-guided photothermal therapy (PTT) can enhance therapeutic efficacy and enable precise treatment of glioma. Goal(s): To develop a tumor cell membrane (CM)-camouflaged theranostic nanoagent , enabling photothermal imaging (PI) and MR dual-modal imaging -guided glioblastoma therapy. Approach: MPDA was firstly chelated with ferric ion (Fe3+), and then loaded with ICG via electrostatic/hydrophobic interactions. Finally, the MPDA-Fe3+-ICG NPs was coated with C6 glioma CM. Results: NPs exhibited superior photothermal and MR imaging performance, its T1 relativity (r1 = 25.6 mM−1S−1) is approximately 6 folders of the commercial Gd-DTPA. Endowing PI/MRI dual-modal imaging -guided remarkable therapeutic efficiency and minimal side effects. Impact: This study illustrates that the highly integrated and biocompatible MPDA-based NPs can serve as a versatile nanoplatform by loading different imaging molecules and drugs for multi-modal imaging and cancer combination therapy.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: